| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acyl glucuronide reactivity in perspective
|
Bradshaw, Peter R.
|
|
|
25 |
9 |
p. 1639-1650
|
artikel
|
| 2 |
Advanced glycation end products in diabetes, cancer and phytochemical therapy
|
Dariya, Begum
|
|
|
25 |
9 |
p. 1614-1623
|
artikel
|
| 3 |
Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling
|
Zhao, Linlin
|
|
|
25 |
9 |
p. 1624-1638
|
artikel
|
| 4 |
Bayer’s in silico ADMET platform: a journey of machine learning over the past two decades
|
Göller, Andreas H.
|
|
|
25 |
9 |
p. 1702-1709
|
artikel
|
| 5 |
Breakthrough therapy-designated oncology drugs: are they rightfully criticized?
|
Mulder, Jorn
|
|
|
25 |
9 |
p. 1580-1584
|
artikel
|
| 6 |
Cancer stem cells and nanomedicine: new opportunities to combat multidrug resistance?
|
Dalpiaz, Alessandro
|
|
|
25 |
9 |
p. 1651-1667
|
artikel
|
| 7 |
Contents page 1
|
|
|
|
25 |
9 |
p. i
|
artikel
|
| 8 |
Contents page 2
|
|
|
|
25 |
9 |
p. ii
|
artikel
|
| 9 |
Degraders early developability assessment: face-to-face with molecular properties
|
Ermondi, Giuseppe
|
|
|
25 |
9 |
p. 1585-1591
|
artikel
|
| 10 |
Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19
|
Bose, Rajendran J.C.
|
|
|
25 |
9 |
p. 1559-1560
|
artikel
|
| 11 |
3D printing for drug delivery and biomedical applications
|
Beg, Sarwar
|
|
|
25 |
9 |
p. 1668-1681
|
artikel
|
| 12 |
Emerging vaccine delivery systems for COVID-19
|
Theobald, Nigel
|
|
|
25 |
9 |
p. 1556-1558
|
artikel
|
| 13 |
Engineering extracellular matrix to improve drug delivery for cancer therapy
|
He, Xiaocong
|
|
|
25 |
9 |
p. 1727-1734
|
artikel
|
| 14 |
Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications
|
Sisignano, Marco
|
|
|
25 |
9 |
p. 1744-1753
|
artikel
|
| 15 |
Following the Science? Or are we sacrificing the arts?
|
Carney, Stephen L.
|
|
|
25 |
9 |
p. 1553-1555
|
artikel
|
| 16 |
From patent to patient: analysing access to innovative cancer drugs
|
Sharpe, Eva
|
|
|
25 |
9 |
p. 1561-1568
|
artikel
|
| 17 |
Human microbial metabolite mimicry as a strategy to expand the chemical space of potential drugs
|
Li, Hao
|
|
|
25 |
9 |
p. 1575-1579
|
artikel
|
| 18 |
Interfering with S100B–effector protein interactions for cancer therapy
|
Wu, Ke-Jia
|
|
|
25 |
9 |
p. 1754-1761
|
artikel
|
| 19 |
Learning from history: do not flatten the curve of antiviral research!
|
Bobrowski, Tesia
|
|
|
25 |
9 |
p. 1604-1613
|
artikel
|
| 20 |
Modulating the modulators: regulation of protein arginine methyltransferases by post-translational modifications
|
Hartley, Antja-Voy
|
|
|
25 |
9 |
p. 1735-1743
|
artikel
|
| 21 |
Noncellular screening for the discovery of protein–protein interaction modulators
|
Kieffer, Charline
|
|
|
25 |
9 |
p. 1592-1603
|
artikel
|
| 22 |
PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer
|
Zhu, Haiying
|
|
|
25 |
9 |
p. 1762-1771
|
artikel
|
| 23 |
Polymer–drug conjugates: recent advances and future perspectives
|
Thakor, Pradip
|
|
|
25 |
9 |
p. 1718-1726
|
artikel
|
| 24 |
Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors
|
Ma, Hongguang
|
|
|
25 |
9 |
p. 1682-1692
|
artikel
|
| 25 |
The rise of molecular simulations in fragment-based drug design (FBDD): an overview
|
Bissaro, Maicol
|
|
|
25 |
9 |
p. 1693-1701
|
artikel
|
| 26 |
The upside of being a digital pharma player
|
Schuhmacher, Alexander
|
|
|
25 |
9 |
p. 1569-1574
|
artikel
|
| 27 |
Treatments of trimethylaminuria: where we are and where we might be heading
|
Schmidt, Aaron C.
|
|
|
25 |
9 |
p. 1710-1717
|
artikel
|
| 28 |
WITHDRAWN: Petite miracles: insight into the nano-management of scarless wound healing
|
Pan, Bei Ho
|
|
|
25 |
9 |
p. 1772
|
artikel
|
Tijdschrift beschrijving